Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently... see more

Recent & Breaking News (OTCPK:ARLZQ)

Research Reports Coverage on Biotech Stocks -- Cerulean Pharma, AveXis, TG Therapeutics, and Aralez Pharma

PR Newswire February 8, 2017

Aralez Pharmaceuticals unveils new office in Ireland

PR Newswire Europe Non Regulatory February 2, 2017

Aralez Announces Issuance Of Additional U.S. Patent For Yosprala

PR Newswire January 11, 2017

Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040

PR Newswire January 9, 2017

Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan

GlobeNewswire January 9, 2017

Aralez Provides Update On PBM Formulary Status For Yosprala

PR Newswire January 9, 2017

15 Stocks With The Highest Forecast Sales Growth

Benzinga.com  December 23, 2016

Aralez Added To The NASDAQ Biotechnology Index

PR Newswire December 19, 2016

Research Reports Initiation on Biotech Stocks -- Pacific Biosciences of California, Aralez Pharma, Cerus, and Pain Therapeutics

PR Newswire December 19, 2016

Aralez Announces Commercial Launch Of BLEXTEN™ In Canada

PR Newswire December 19, 2016

Aralez Provides Update on PBM Formulary Status for Yosprala

PR Newswire December 15, 2016

Aralez to Participate at Two Upcoming Healthcare Conferences

PR Newswire November 30, 2016

New Post-Hoc Analysis Supports YOSPRALA™ Efficacy And Safety In Previous Heart Attack Patients Who Need Daily Aspirin Therapy To Prevent A Second Cardiovascular Event

PR Newswire November 14, 2016

Aralez Reports Third Quarter 2016 Financial Results

Canada NewsWire November 7, 2016

Research Reports Coverage on Biotech Stocks -- Tesaro, Aralez Pharma, Rexahn Pharma, and CytRx

PR Newswire November 7, 2016

Aralez to Present at the Jefferies London Healthcare Conference

Canada NewsWire November 2, 2016

Aralez Completes Acquisition Of Toprol-XL® And Its Authorized Generic From AstraZeneca

Canada NewsWire October 31, 2016

Aralez To Announce Third Quarter 2016 Results On November 7, 2016

PR Newswire October 24, 2016

Mid-Morning Market Update: Markets Open Higher; Darden Profit Beats Estimates

Benzinga.com  October 4, 2016

15 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  October 4, 2016